23andMe, founded in April 2006 by Linda Avey, Paul Cusenza, and Anne Wojcicki. The company has not officially endorsed a plan to participate in an IPO.
23andMe provides at-home, consumer genetic testing and was the first FDA-approved direct-to-consumer genetic sequencing supplier. More recently, 23andMe has leveraged its genetic database in pursuit of pharmaceutical drug development. The company has raised nearly $800 million in Venture Capital funding from investors including GlaxoSmithKline, Pegasus Tech Ventures, MicroVentures, G Squared, Sapphire Ventures, Sequoia Capital, SharesPost, Fidelity, GV, and Genetech. It has been widely reported that 23andMe last raised $300 million in July 2018 at a post-money valuation of $2.5 billion.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
12/23/2020 | Series F-1 | $385MM | $xx.xx | $2.59B | GlaxoSmithKline, NewView Capital, Sequoia Capital | |
Price per Share
$xx.xx
Shares Outstanding
22,190,201
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
600.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
GlaxoSmithKline, NewView Capital, Sequoia Capital
|
||||||
09/12/2017 | Series F | $250MM | $xx.xx | $1.75B | Sequoia Capital, Euclidean Capital, Altimeter Capital, Wallenberg Foundation, Fidelity Management, Casdin Capital | |
Price per Share
$xx.xx
Shares Outstanding
18,006,075
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
600.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Sequoia Capital, Euclidean Capital, Altimeter Capital, Wallenberg Foundation, Fidelity Management, Casdin Capital
|
||||||
06/08/2015 | Series E | $115.25MM | $xx.xx | $1.1B | Fidelity Management, Casdin Capital, WuXi Venture Fund, Xfund, Illumina, New Enterprise Associates, MPM Capital, Google Ventures | |
Price per Share
$xx.xx
Shares Outstanding
10,644,057
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
600.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Fidelity Management, Casdin Capital, WuXi Venture Fund, Xfund, Illumina, New Enterprise Associates, MPM Capital, Google Ventures
|
||||||
12/10/2012 | Series D | $58.45MM | $xx.xx | $288.74MM | New Enterprise Associates, Google Ventures, MPM Capital, Other Individual Investors | |
Price per Share
$xx.xx
Shares Outstanding
14,435,636
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
600.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
New Enterprise Associates, Google Ventures, MPM Capital, Other Individual Investors
|
||||||
11/10/2010 | Series C | $31.18MM | $xx.xx | $184.5MM | Johnson & Johnson, Roche Venture Fund, MPM Capital, New Enterprise Associates, Google Ventures | |
Price per Share
$xx.xx
Shares Outstanding
9,898,011
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
600.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Johnson & Johnson, Roche Venture Fund, MPM Capital, New Enterprise Associates, Google Ventures
|
||||||
12/23/2009 | Series B | $27.78MM | $xx.xx | $150.5MM | Google, New Enterprise Associates, Other Individual Investors | |
Price per Share
$xx.xx
Shares Outstanding
9,048,560
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
600.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Google, New Enterprise Associates, Other Individual Investors
|
||||||
05/22/2007 | Series A | $8.95MM | $xx.xx | $48.5MM | Google Ventures, Genentech, New Enterprise Associates, Mohr Davidow Ventures | |
Price per Share
$xx.xx
Shares Outstanding
7,119,936
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
600.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Google Ventures, Genentech, New Enterprise Associates, Mohr Davidow Ventures
|